Menu

News

ETH develops a freezing method for textured legumes
ETH researchers use directional freezing to give whole-legume preparations a fibrous texture without extracting isolated proteins.
Oncobit raises over CHF 1.9M
Oncobit develops liquid biopsy tests and software for monitoring cancer.
Virometix raises USD 15M
Virometix develops synthetic vaccines against infectious diseases.
arcoris bio raises CHF 6.3M seed
arcoris bio develops biomarker detection technology for digital pathology.
CUTISS raises CHF 31M Series C extension
CUTISS develops personalized skin grafts and automated tissue manufacturing.
cellvie raises USD 5M
cellvie develops mitochondrial therapies for damaged organs.
Mabylon raises CHF 30M
Mabylon develops antibodies for allergies and inflammatory diseases.
vVARDIS raises USD 50M
vVARDIS develops treatments for repairing early tooth decay without drilling.
EvlaBio raises EUR 21M seed
EvlaBio develops antibodies for heart complications of chronic kidney disease.
SEITO Biologics raises over CHF 2.8M
SEITO develops regulatory T-cell therapies for autoimmune and inflammatory diseases.
GlycoEra raises USD 130M Series B
GlycoEra develops protein degraders for autoimmune diseases.
Taiho to acquire Araris
Araris develops antibody-drug conjugates for cancer treatment.
CellX raises CHF 1.7M pre-seed
CellX develops bacterial treatments for breaking down industrial pollutants.
vVARDIS raises USD 35M
vVARDIS develops treatments for repairing early tooth decay without drilling.
Numab raises CHF 50M Series C extension
Numab develops multispecific antibodies for inflammatory diseases and cancer.
Oncobit raises CHF 1.47M pre-Series A
Oncobit develops liquid biopsy tests and software for monitoring cancer.
Sallea raises USD 2.6M pre-seed
Sallea develops edible scaffolds for growing cultivated meat and fish.
Somagenetix raises CHF 10M Series A
Somagenetix develops gene therapies for inherited immune disorders.
ImmunOs raises USD 11M Series C
ImmunOs develops immune-modulating therapies for cancer and autoimmune diseases.
Rivia raises EUR 3M seed
Rivia develops software for analysing clinical trial data.
20 of 27

Confirm